Research
Hormonal
HIIT improves cardiovascular function in patients with metabolic diseases by increasing end-diastolic volume, stroke volume, and flow-mediated dilation, and reducing arterial stiffness.
HIIT not only helps your muscles handle sugar but also strengthens your heart and blood vessels. It increases the volume of blood your heart pumps (stroke volume) and improves the flexibility of your arteries (flow-mediated dilation), which are key markers of cardiovascular health.
ModerateSupportsMEDIUM confidence
Changes in skeletal muscle... Changes to cardiovascular system... 1 Torsion = myocardial damage... 2 EDV = preload... 3 Ca2+ handling = SV + EF... 4 FMD = O2 supply
Why this rating
The paper reviews multiple studies showing these effects, but specific quantitative data varies.
Source
High-intensity interval training: a review of its impact on glucose control and cardiometabolic health
Sophie Cassidy et al. · Diabetologia · 2016
DOI 10.1007/s00125-016-4106-1
narrative_reviewCited 231×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High-intensity interval training (HIIT) induces skeletal muscle molecular adaptations, including increased GLUT-4 content and mitochondrial biogenesis, which improve glucose disposal and insulin sensitivity in patients with metabolic diseases.Moderate
- A single session of HIIT reduces same-day postprandial glucose excursions in individuals with impaired fasting glucose or type 2 diabetes, offering acute metabolic benefits.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →